Trial reportRadiation oncology (London, England)2017
Long-term follow-up after stereotactic radiosurgery of intracanalicular acoustic neurinoma.
Trial report in Radiation oncology (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Stereotactic radiosurgery for treating meningiomas eligible for complete resection.Radiation oncology (London, England) · 2021Trial
- Integrating artificial intelligence with Gamma Knife radiosurgery in treating meningiomas and schwannomas: a review.Neurosurgical review · 2025Review
- Hearing Function after CyberKnife for Vestibular Schwannoma: A Systematic Review.International archives of otorhinolaryngology · 2024Review
- The Recent Management of Vestibular Schwannoma Radiotherapy: A Narrative Review of the Literature.Journal of clinical medicine · 2024Review
- Pseudoprogression of Vestibular Schwannoma after Stereotactic Radiosurgery with CyberknifeCancers · 2023Article
- Does preoperative gamma knife treatment affect the result of microresection of vestibular schwannoma?Journal of neuro-oncology · 2022Article
- Tumor control and hearing preservation after radiosurgery of intracanalicular vestibular schwannomas - systematic review.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2022Review
- Review
- [Macroscopic and microscopic changes of the vestibulocochlear nerve after Gamma Knife treatment].HNO · 2022Article
- Article
- Evaluation of Brainstem Subcortical Auditory Pathways with Diffusion Tensor Imaging After Gamma Knife Radiosurgery in Intracanalicular Vestibular Schwannoma.Medeniyet medical journal · 2021Article
- Stereotactic radiosurgery of benign brain tumors in elderly patients: evaluation of outcome and toxicity.Radiation oncology (London, England) · 2020Article
- Outcome and toxicity analysis of single dose stereotactic radiosurgery in vestibular schwannoma based on the Koos grading system.Scientific reports · 2020Article
- Twelve-year results of LINAC-based radiosurgery for vestibular schwannomas.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2020Article
- Stereotactic Radiosurgery for Vestibular Schwannomas: Reducing Toxicity With 11 Gy as the Marginal Prescribed Dose.Frontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of solely intracanalicular acoustic neurinoma (iAN) includes observation, microsurgical resection and radiation therapy. Treatment goals are long-term tumor control, hearing preservation and concurrently low side-effects. Stereotactic radiosurgery (SRS) has evolved as an alternative first-line treatment for small AN. Here we report about the long-term follow-up of a unique cohort of patients with iAN after LINAC or Cyberknife® based SRS.
methodsIn this single center retrospective analysis, we included all patients with iAN who underwent single session LINAC or Cyberknife® based SRS between 1993 and 2015, and who had a minimum follow-up period of six weeks. Patient data were analyzed in terms of radiological and clinical tumor control (no further treatment necessary), subjective preservation of serviceable hearing, objective change in pure tone averages (PTA), and adverse events rated by the Common Terminology Criteria for Adverse Events (CTCAE; v4.03).
resultsForty-nine patients (f/m = 21/28, median age 54 ± 12, range 20-77 years) were identified. Mean tumor volumes were 0.24 ± 0.12 cm
conclusionSRS for iAN shows long-term reliable tumor control with a high rate of hearing preservation without considerable permanent side effects, and can be proposed as a safe and effective treatment alternative to microsurgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.